10 reports

THE DRUG CANDIDATE ACTS BY TARGETING DIPEPTIDASE-##.

  • Antifungal
  • Blood Disease
  • Digestive System Disorder
  • Protein Therapy
  • Research And Development

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Antifungal
  • Blood Disease
  • Digestive System Disorder
  • Protein Therapy
  • United States

The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others.

  • Blood Disease
  • Digestive System Disorder
  • Protein Therapy
  • Therapy
  • United States

THE DRUG CANDIDATE IS A ## MER PEPTIDE ACTS BY TARGETING PROGRAMMED CELL DEATH ## LIGAND ## (PD-L##).

  • Blood Disease
  • Digestive System Disorder
  • Pharmaceutical
  • Protein Therapy
  • Therapy

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Antifungal
  • Blood Disease
  • Digestive System Disorder
  • Protein Therapy
  • United States

One patient had a fatal SAE, which was not drug related.

  • Antifungal
  • Blood Disease
  • Cancer
  • Digestive System Disorder
  • Protein Therapy

One patient had a fatal SAE, which was not drug related.

  • Antifungal
  • Blood Disease
  • Digestive System Disorder
  • Protein Therapy
  • United States

Two out of the six were considered possibly related to study drug: one in Group ## and one in Group ##.

  • Antifungal
  • Blood Disease
  • Digestive System Disorder
  • Pathology
  • Protein Therapy

Sanofi also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women' s health; and vitamins, minerals and supplements.

  • Blood Disease
  • Digestive System Disorder
  • Immunotherapy
  • Protein Therapy
  • MediciNova, Inc.

One patient had a fatal SAE, which was not drug related.

  • Antifungal
  • Blood Disease
  • Digestive System Disorder
  • Protein Therapy
  • United States